Strategic partnerships Rectify has a recent strategic research and licensing collaboration with Boehringer Ingelheim to accelerate CKD and related conditions, signaling openness to co-development and licensing deals with large pharma. This creates sales opportunities around collaboration frameworks, joint development funding, and access to larger distribution channels.

Clinical candidate spotlight The company has announced RTY-406, a dual-targeted PFM for ABCB4 and BSEP, with presence at major industry meetings, suggesting a ready-to-discuss clinical program and potential for in-licensing discussions or sponsored development partnerships around hepatobiliary indications.

Therapeutic focus PFMs aim to restore membrane protein function across liver, cardio-renal-metabolic, and neurodegenerative diseases, indicating multiple high-value target spaces for research collaborations, platform licensing, or strategic investments in areas with high unmet need and attractive market dynamics.

Early-stage traction With a recent Series A funding round totaling around one hundred million dollars and a revenue range of one to ten million, Rectify shows growing commercial and R&D momentum, making them a receptive partner for early-phase discovery agreements, milestone-based deals, and supply of research tools or services.

Leadership and credibility Key hires and board-level representation, including a notable CMO appointment and advisory board additions, combined with seed support from Atlas Venture and notable investors, enhance credibility for prospective partners seeking venture-backed biotech collaboration opportunities and co-development negotiations.